Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

This open-label, multicenter, three cohorts, phase II study is designed to assess a combination of Zanubrutinib/Venetoclax/Glofitamab or Venetoclax/Glofitamab in high-risk subjects with either first line or R/R Mantle Cell Lymphoma (MCL). Three independent cohorts will be run: * Cohort A will include subjects with a primary refractory or progressive disease within 24 months from initiation of first line treatment (POD 24). * Cohort B will be open for subjects with R/R MCL and refractory or progressive to a BTK inhibitor given previously (\>24 months if first line). * Cohort C will only enrol

Trial Details

NCT ID
NCT06558604
Phase
PHASE2
Sponsor
The Lymphoma Academic Research Organisation
Status
RECRUITING
Cancer Type
Mantle Cell Lymphoma Lymphoma
Interventions
  • Obinutuzumab
  • Glofitamab
  • Venetoclax Oral Product
  • Zanubrutinib Oral Capsule
Locations (sample)
  • Bruges, Belgium|51.20892,3.22424
  • Brussels, Belgium|50.85045,4.34878
  • Liège, Belgium|50.63373,5.56749
  • Yvoir, Belgium|50.3279,4.88059
  • Créteil, France|48.79266,2.46569

Key Eligibility Criteria

  • Participant must be primary refractory or in progression within 24 months from initiation of first line treatment (POD24 defined as time between D1…
  • Primary refractory participants (i.e., with a progressive disease) to the BTKi and Venetoclax combination will not be eligible.
  • In cohort B, participant must meet the following inclusion criterion:
  • Participant must be R/R MCL and refractory or progressive to a BTK inhibitor given in a previous line of treatment (the number of treatment lines i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mantle Cell Lymphoma Lymphoma Trials on Trialify →